Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors
For most inflammatory skin diseases topical glucocorticosteroids and traditional oral immunosuppressive drugs remain the principle treatment choices, but this has started to change. A deeper understanding in individual disease pathogenesis, basic immune mechanisms and molecular signalling pathways, together with advances in pharmaceutical drug development, allow us to interfere more precisely with disease‐related factors. Some examples of inflammation‐controlling interventions include antibodies neutralizing disease‐associated cytokines, and small molecules targeting intracellular pathways relevant to cytokine production or cytokine signalling. So far, this is best established for psoriasis, an inflammatory skin disease dominated by Th17 cytokines. In this review, we focus on chronic inflammatory skin diseases where cytokines using type I/II cytokine receptors play a dominant role in disease pathogenesis and where novel treatments with inhibitors of the JAK/STAT pathway are already under clinical investigation. To better understand the rationale of using JAK/STAT inhibitors in the discussed skin diseases, we give an overview of important genetic and immunological associations with the JAK/STAT pathway and summarize the stage of clinical development of small molecular inhibitors. JAK/STAT inhibitors will presumably find wide application in dermatology, since they can be applied not only systematically but also topically for the treatment of inflammatory skin diseases. Cytokines that signal through the JAK/STAT signalling pathway are critically implicated in the pathogenesis of immune‐mediated skin diseases such as alopecia areata and others. We summarize the current understanding on the immune signature of different types of skin inflammation and focus on promising therapeutics interfering with the JAK/STAT pathway..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
European journal of immunology - 47(2017), 7, Seite 1096-1107 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Welsch, Katharina [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1002/eji.201646680 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1994056134 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1994056134 | ||
| 003 | DE-627 | ||
| 005 | 20230715052127.0 | ||
| 007 | tu | ||
| 008 | 170721s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1002/eji.201646680 |2 doi | |
| 028 | 5 | 2 | |a PQ20170721 |
| 035 | |a (DE-627)OLC1994056134 | ||
| 035 | |a (DE-599)GBVOLC1994056134 | ||
| 035 | |a (PRQ)p1001-20e6d98ec759a37c8c483f5660400e0d4b710c31bc576bbc0fc631ae8e3e4b963 | ||
| 035 | |a (KEY)0011453720170000047000701096targetingjakstatsignallingininflammatoryskindiseas | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 100 | 1 | |a Welsch, Katharina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a For most inflammatory skin diseases topical glucocorticosteroids and traditional oral immunosuppressive drugs remain the principle treatment choices, but this has started to change. A deeper understanding in individual disease pathogenesis, basic immune mechanisms and molecular signalling pathways, together with advances in pharmaceutical drug development, allow us to interfere more precisely with disease‐related factors. Some examples of inflammation‐controlling interventions include antibodies neutralizing disease‐associated cytokines, and small molecules targeting intracellular pathways relevant to cytokine production or cytokine signalling. So far, this is best established for psoriasis, an inflammatory skin disease dominated by Th17 cytokines. In this review, we focus on chronic inflammatory skin diseases where cytokines using type I/II cytokine receptors play a dominant role in disease pathogenesis and where novel treatments with inhibitors of the JAK/STAT pathway are already under clinical investigation. To better understand the rationale of using JAK/STAT inhibitors in the discussed skin diseases, we give an overview of important genetic and immunological associations with the JAK/STAT pathway and summarize the stage of clinical development of small molecular inhibitors. JAK/STAT inhibitors will presumably find wide application in dermatology, since they can be applied not only systematically but also topically for the treatment of inflammatory skin diseases. Cytokines that signal through the JAK/STAT signalling pathway are critically implicated in the pathogenesis of immune‐mediated skin diseases such as alopecia areata and others. We summarize the current understanding on the immune signature of different types of skin inflammation and focus on promising therapeutics interfering with the JAK/STAT pathway. | ||
| 540 | |a Nutzungsrecht: © 2017 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim | ||
| 650 | 4 | |a Autoimmunity | |
| 650 | 4 | |a Skin | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a JAK inhibitors | |
| 650 | 4 | |a JAK/STAT | |
| 650 | 4 | |a Helper cells | |
| 650 | 4 | |a Medical services | |
| 650 | 4 | |a Disease control | |
| 650 | 4 | |a Pathogenesis | |
| 650 | 4 | |a Immunosuppressive agents | |
| 650 | 4 | |a Neutralizing | |
| 650 | 4 | |a Psoriasis | |
| 650 | 4 | |a Lymphocytes T | |
| 650 | 4 | |a Cytokine receptors | |
| 650 | 4 | |a Cytokines | |
| 650 | 4 | |a Inhibitors | |
| 650 | 4 | |a Diseases | |
| 650 | 4 | |a Drugs | |
| 650 | 4 | |a Intracellular signalling | |
| 650 | 4 | |a Disease | |
| 650 | 4 | |a Pathways | |
| 650 | 4 | |a Biotechnology industry | |
| 650 | 4 | |a Immunology | |
| 650 | 4 | |a Dermatology | |
| 650 | 4 | |a Receptors | |
| 650 | 4 | |a Developmental stages | |
| 650 | 4 | |a Drug development | |
| 650 | 4 | |a Antibodies | |
| 650 | 4 | |a Skin diseases | |
| 650 | 4 | |a Signalling | |
| 650 | 4 | |a Signal transduction | |
| 700 | 1 | |a Holstein, Julia |4 oth | |
| 700 | 1 | |a Laurence, Arian |4 oth | |
| 700 | 1 | |a Ghoreschi, Kamran |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of immunology |d Weinheim : Wiley, 1971 |g 47(2017), 7, Seite 1096-1107 |w (DE-627)129288713 |w (DE-600)120108-6 |w (DE-576)014470306 |x 0014-2980 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2017 |g number:7 |g pages:1096-1107 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1002/eji.201646680 |3 Volltext |
| 856 | 4 | 2 | |u http://onlinelibrary.wiley.com/doi/10.1002/eji.201646680/abstract |
| 856 | 4 | 2 | |u https://search.proquest.com/docview/1917268034 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_48 | ||
| 912 | |a GBV_ILN_267 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_2219 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2017 |e 7 |h 1096-1107 | ||